scholarly journals Ibandronate Prevents Bone Loss and Reduces Vertebral Fracture Risk in Male Cardiac Transplant Patients: A Randomized Double-Blind, Placebo-Controlled Trial*

2009 ◽  
Vol 24 (7) ◽  
pp. 1335-1344 ◽  
Author(s):  
Astrid Fahrleitner-Pammer ◽  
Jutta Claudia Piswanger-Soelkner ◽  
Thomas Rudolf Pieber ◽  
Barbara Maria Obermayer-Pietsch ◽  
Stefan Pilz ◽  
...  
Keyword(s):  
Vertebral Fracture ◽  
Bone Loss ◽  
Fracture Risk ◽  
Controlled Trial ◽  
Cardiac Transplant ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Transplant Patients ◽  
Vertebral Fracture Risk

A Double Blind, Placebo-Controlled Trial of Ipriflavone for Prevention of Postmenopausal Spinal Bone Loss

1997 ◽  
Vol 61 (2) ◽  
pp. 142-147 ◽  
Author(s):  
D. Agnusdei ◽  
G. Crepaldi ◽  
G. Isaia ◽  
G. Mazzuoli ◽  
S. Ortolani ◽  
...  
Keyword(s):  
Bone Loss ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals Glucocorticoid-Induced Bone Loss Is Associated with Abnormal Intravertebral Areal Bone Mineral Density Distribution

2013 ◽  
Vol 2013 ◽  
pp. 1-9 ◽  
Author(s):  
Louise I. Manning ◽  
Andrew M. Briggs ◽  
Sharon Van Doornum ◽  
Ashwini Kale ◽  
Susan Kantor ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Vertebral Fracture ◽  
Bone Loss ◽  
Fracture Risk ◽  
Bone Mineral ◽  
Vertebral Body ◽  
Areal Bone Mineral Density ◽  
Primary Osteoporosis ◽  
Mineral Density ◽  
Vertebral Fracture Risk

Individuals with glucocorticoid-induced osteoporosis experience vertebral fractures at an increased rate and at higher vertebral areal bone mineral density (aBMD) than individuals with primary osteoporosis. Standard posteroanterior- (PA-) projection dual energy X-ray absorptiometry (DXA) lacks the diagnostic sensitivity required for reliable estimation of vertebral fracture risk in individuals. Assessment of subregional vertebral aBMD using lateral-projection DXA may improve the predictive value of DXA parameters for fracture. One hundred and four individuals were recruited and grouped for this study: primary osteoporosis with no history of vertebral fracture (n=43), glucocorticoid-induced bone loss (n=13), and healthy controls (n=48). Standard PA-projection and supine-lateral scans were performed, and lateral scans were analysed according to an established protocol to measure aBMD within 6 subregions. Main effects for subregion and group were assessed and observed, by ANCOVA. Ratios were calculated between subregions and compared between groups, to overcome the potentially confounding influence of variability in subregional geometry. Significantly lower values were observed in the glucocorticoid group for the ratios of (i) anterior subregion: whole vertebral body and (ii) posterior: whole vertebral body when compared to the primary osteoporosis and control groups (P<0.05). Lower anterior subregional aBMD in individuals on glucocorticoid therapy may help to explain the increased vertebral fracture risk in this patient group.

Vitamin K2 supplementation does not influence bone loss in early menopausal women: a randomised double-blind placebo-controlled trial

2009 ◽  
Vol 21 (10) ◽  
pp. 1731-1740 ◽  
Author(s):  
N. Emaus ◽  
C. G. Gjesdal ◽  
B. Almås ◽  
M. Christensen ◽  
A. S. Grimsgaard ◽  
...  
Keyword(s):  
Bone Loss ◽  
Controlled Trial ◽  
Vitamin K2 ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Menopausal Women

Clinical efficacy of specific immunotherapy to cat dander: a double-blind placebo-controlled trial

1997 ◽  
Vol 27 (8) ◽  
pp. 860-867 ◽  
Author(s):  
V.A. VARNEY ◽  
J. EDWARDS ◽  
K. TABBAH ◽  
H. BREWSTER ◽  
G. MAVROLEON ◽  
...  
Keyword(s):  
Clinical Efficacy ◽  
Specific Immunotherapy ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo
Sign in / Sign up

Export Citation Format

Share Document